Pharmaessentia Corp. · TWSE:6446
Pharmaessentia — Fubon Securities' Investor Conference 2026
33 slides from Pharmaessentia's conference presentation, Mar 3, 2026
Slide 1: PharmaEssentia
PharmaEssentia TWSE 6446 PharmcaEssentia
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation contains forward-looking statements, including statements regarding the plans and expectations for commercializing BESREMi® in the United States and globally, and the potential benefits or competitive position of BESREMi® . For those statements, we claim
Slide 3: Q4'25 Financial Results
Q4’25 Financial Results PharmaEssentia
Slide 4: Q4'25 revenue +25% QoQ; FY25 reached USD 504M
Q4’25 revenue +25% QoQ; FY25 reached USD 504M (halfway to blockbuster) Unit : NTD 100 million ► 2025 revenue ： 15.63 billion 50 48.81 ► 2024 revenue ： 9.73 billion 45 40 38.94 36.02 35 32.57 30.60 30 27.10 25 23.10 20 16.50 15 10 5 0 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25
Slide 5: FY2025 Operating revenue increased 61% YoY, with strong operating expense discipline
FY2025 Operating revenue increased 61% YoY, with strong operating expense discipline Unit : NTD 100 million Operating Revenue Operating Expense 160 156.34 160 140 140 120 120 100 97.34 90.22 100 80 80 68.22 Selling 39% 60 60 Selling 36% Admin 40 40 23% Admin 26% 20 20 R&D 38% R&D 38% 0 0 2024 2025 2
Slide 6: FY2025 Net operating income surged 184% YoY; Net income grew 70% YoY
FY2025 Net operating income surged 184% YoY; Net income grew 70% YoY Unit : NTD 100 million Net Operating Income Net Income 60 60 49.28 50.45 50 50 40 40 30 30 29.66 20 17.36 20 10 10 0 0 2024 2025 2024 2025 FY24 FY25 FY24 FY25
Slide 7: FY2025 delivered strong net operating income, driving operating margin to 31%
FY2025 delivered strong net operating income, driving operating margin to 31% Unit : NTD 100 million Item FY24 FY25 YoY Operating Revenue 97.34 156.34 Gross Margin 88% 89% +1 ppts Operating Expense (68.22) (90.22) Operating Margin 18% 31% +13 ppts Total non-operating 12.59 0.55 income and expenses N
Slide 8: FY2025 EPS hits record high of NTD 13.64 (+69% YoY)
FY2025 EPS hits record high of NTD 13.64 (+69% YoY) Unit: NTD 20 18 16 14 13.64 12 10 8.06 8 6 4 2 0 2024 2025 FY24 FY25
Slide 9: Stock dividends and cash dividends distribution
Stock dividends and cash dividends distribution (approved by the Board, to be proposed at the May shareholders’ meeting) Distribution NT$ per share Cash Dividends 1.5 Stock Dividends 1.1 FY2025 Net Income (NTD Thousands): 5,045,167
Slide 10: Company Overview
Company Overview PharmaEssentia
Slide 11: A fully integrated innovative biopharmaceutical company
A fully integrated innovative biopharmaceutical company Our Commercial Product and R&D Pipelines PharmaEssentia 6446.TW • FOUNDED • COMMERCIAL ROPEG Growth Drivers OPERATIONS (Ropeginterferon alfa-2b) 2003 Boston (USA), • Approved for adults with polycythemia • Geographic expansion for PV market • H
Slide 12: The global MPN treatment market exceeds USD billion, with ROPEG poised to lead
The global MPN treatment market exceeds USD 20 billion, with ROPEG poised to lead the next wave of innovation Myeloproliferative Neoplasm (MPN) Global MPN Market size ( 2025 ) CAGR Global MPN Market size ( 2035 ) $15.33Bn (2025-2035) 3.32% $21.25Bn Unit : USD Billion 10.00 10.00 Global PV Market Glo
Slide 13: A significant opportunity just from US Patients with PV
A significant opportunity just from US Patients with PV Geographically Expanding ROPEG's Reach to Benefit More Patients with PV Worldwide 148K 163K Essential Thrombocythemia (ET) • SURPASS – data readout Jan 6, 2025 • NCCN Guideline listed (Version 1.2026) • 2025 China, Taiwan, Japan submission Poly
Slide 14: ROPEG approved in nearly 50 Countries for PV
ROPEG approved in nearly 50 Countries for PV, with global patient access steadily expanding EU Canada Korea China Middle East U.S. Japan Mexico Taiwan Vietnam H.K. Brazil Macau Colombia Singapore Malaysia Argentina Approved In Preparation
Slide 15: ROPEG recommended by NCCN Guidelines as the only first-line therapy for PV
ROPEG recommended by NCCN Guidelines as the only first-line therapy for both low-risk and high-risk PV Key updates on PV treatment in the NCCN Guidelines Treatment For Low-Risk PV NCCN 2025 Version 2 age 60 years or younger with no history of thrombosis Guideline Symptomatic with Preferred regimens:
Slide 16: Proven long-term safety, efficacy, and effective reduction of driver mutations
Proven long-term safety, efficacy, and effective reduction of driver mutations Approved in 2021 by PROUD / CONTINUATION PV Study Ropeginterferon alfa-2b (CONTI-PV3) USFDA Median JAK2 V617F Allele Burden (%) 60 76.2% 52 50 Overall CHR 50 45 44 45 45 48 Median JAK2V617 Allele Discontinued patients in
Slide 17: ROPEG recommended by NCCN Guidelines as the only first-line therapy for PV
ROPEG recommended by NCCN Guidelines as the only first-line therapy for both low-risk and high-risk PV Key updates on PV treatment in the NCCN Guidelines Treatment For Low-Risk PV NCCN 2025 Version 2 age 60 years or younger with no history of thrombosis Guideline Symptomatic with Preferred regimens:
Slide 18: Earlier Intervention: ROPEG + Phlebotomy for Low-Risk PV
Earlier Intervention: ROPEG + Phlebotomy for Low-Risk PV showed superior reduction of phlebotomy and hematocrit control Takeda and Protagonist P < 0.001 P = 0.006 100 January 5th, 2026 81.3 81.3 80 Announce Submission of New Drug Application (NDA) for Rusfertide Response (%) 58.7 for Treatment of Po
Slide 19: Expected to obtain U.S. and Global ROPEG ET drug approvals in 2026
Expected to obtain U.S. and Global ROPEG ET drug approvals in 2026, benefiting nearly 100,000 patients ET patient population in the US effectively doubles the market potential 148K 163K ET Essential Thrombocythemia (ET) • SURPASS – data readout Jan 6, 2025 • NCCN Guideline listed (Version 1.2026) Po
Slide 20: A key breakthrough for treatment of ET in 30 Years
Canada Korea China U.S. Japan Taiwan ET regulatory submission completed; approval expected in 2026 A key breakthrough for treatment of ET in 30 Years Submission Completed In Preparation
Slide 21: Clinical Trials Supporting sBLA for Label Expansions
Clinical Trials Supporting sBLA for Label Expansions The results of SURPASS-ET serve as the pivotal evidence for safety and A Phase 3, 52-week, Open-Label, efficacy while EXCEED-ET serve as A Phase 2b, 56-week, A Single-arm, Randomized, Active-controlled confirmatory evidence Multicenter Study to As
Slide 22: SURPASS-ET results garnering international attention
ROPEG’s compelling clinical performance highlighted by SURPASS-ET results garnering international attention Primary Efficacy Endpoint – Durable Modified ELN Response JAK2 Allelic Burden, Baseline and Month 12 at Month 9 and 12 3 60% 2 50% 42.9% 1 40% P = 0.0001 0 Response Rate (%) 30% -1 20% -2 10%
Slide 23: EXCEED-ET shows comparable efficacy to SURPASS-ET
EXCEED-ET shows comparable efficacy to SURPASS-ET (without TSS), with superior results in treatment-naïve patients 70 p<0.0001 70 70 68.0 60.2 60 60 60 Response Rate (%) 52.7 Durable Modified ELN Response Rate Response Rate (%) 50 50 50 at Months 9 and 12 (%) 40 40 40 33.4 30 30 30 20 20 20 10 6.0 1
Slide 24: EXCEED-ET also demonstrates significant reduction of JAK2 allele burden with ROPEG
EXCEED-ET also demonstrates significant reduction of JAK2 allele burden with ROPEG JAK2V617F Allele Frequency CALR Allele Frequency MPL Allele Frequency 10 10 10 Baseline at Month 13 (%) Baseline at Month 13 (%) Baseline at Month 13 (%) 5 Absolute Change from Absolute Change from Absolute Change fro
Slide 25: Groundbreaking achievement: ROPEG now listed in NCCN guidelines
Groundbreaking achievement: ROPEG now listed in NCCN guidelines NCCN Guideline Version 1.2026 TREATMENT FOR HIGH-RISK ET • Manage cardiovascular History of thrombosis at any age; or age >60 years with JAK2 mutation Preferred regimens risk factors Potential indications for change of Clinical trial •
Slide 26: Substantial PMF Patient Population Represents a Critical Market Opportunity
Substantial PMF Patient Population Represents a Critical Market Opportunity to Prevent Progression to Myelofibrosis A High-Value Market Opportunity Driven by the Significant PMF Patient Population 148K Essential Thrombocythemia (ET) 163K • SURPASS – data readout Jan 6, 2025 • NCCN Guideline listed (
Slide 27: ROPEG PMF IIT two-year results gain international recognition
ROPEG PMF IIT two-year results gain consecutive international recognition at ASH, EHA, and ASCO In Early Myelofibrosis, PMF, and Secondary MF, ROPEG has shown significant efficacy, maintaining hemoglobin (Hb) levels and reducing blood cell counts, alongside achieving other key clinical, hematologica
Slide 28: ROPEG powers near-term revenue; HOPE-PMF drives mid- to long-term growth
ROPEG powers near-term revenue; HOPE-PMF drives mid- to long-term growth, with additional new indication anticipated by 2028 Ropeginterferon alfa-2b (P1101) in Pre-fibrotic/ Early PMF Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Clinical Study to Assess Efficacy and Safety of Rop
Slide 29: Zhubei facility ready to supply >100,000 patients
Zhubei facility will be ready to supply for >100,000patients worldwide
Slide 30: ROPEG phase III and IIT trials accelerating, with new indications
ROPEG phase III and IIT trials accelerating, with new indications, driving future growth Oncology and Immunology IND DEVELOPMENT CANDIDATE INDICATION DISCOVERY PHASE 1* PHASE 2* PHASE 3 ENABLING UPDATE Polycythemia Vera (PV) Commercialization Essential ROPEG Under Approval Review Thrombocythemia (ET
Slide 31: Five products entering phase 1 in 2026
Five products entering phase 1 in 2026, strong early-stage oncology and immunology pipeline propelling future growth Oncology and Immunology DEVELOPMENT CANDIDATE INDICATION DISCOVERY IND ENABLING PHASE 1* UPDATE PEG-IL-2 (P11838) Immunology Planned IND in 2026 PEG cytokine PEG-Cytokines Solid Tumor
Slide 32: Four Strategic Forces Accelerating Rapid, Risk-controlled Growth
Billion-Dollar Revenue, Tens of Billions in Ambition: Four Strategic Forces Accelerating Rapid, Risk-controlled Growth Develop novel best-in-class (BiC) and first-in-class (FiC) immune checkpoint inhibitors Top-tier • Advance TCR-T cell therapy targeting both surface and intracellular antigens Innov
Slide 33: Thank You
sience, Better Lives. PharmaEssentia
PharmaEssentia — Fubon Securities' Investor Conference 2026 on 6ix